Corporate name ：KYOWA HAKKO BIO CO., LTD.

Established ：October 1, 2008

Capital： 10,000 Millions of ** Yen

Number of employees： 730 (As of October 1, 2008)

Plants：

Yamaguchi Production Center (Hofu, Ube)

Healthcare Plant (Tsuchiura)

Laboratories ：

Technical Research Laboratory (Hofu)

Healthcare Product Development Center (Tsukuba)

Bioprocess Development Center (Tsukuba)

Corporate activities Manufacture and sale of ：

Amino acids and nucleic acids for pharmaceutical and industrial use, bulk pharmaceuticals.

Parent Corporate：Kyowa Hakko Kirin Co., Ltd.(100%)

1949Establishment of Kyowa Hakko Kogyo1951Introduced production technology of Streptomycin, an anti-tubercular drug from US pharmaceutical company Merck & Co.,Inc.and succeeded in its mass production1956Success of isolation and commercially mass-production of the anticanser drug,MitomycinC. 
Invention of the process of L-Glutamic acid production by fermentation(a world first)
Pioneered the major business industry of amino-acid fermentation.1958Invention of the process of L-Lysin production by fermentation.
Release of a plant growth regulator,Gibberellin Kyowa(Contribution to production of seedless grapes)1969Establishment of Kyowa Hakko USA1973Establishment of Kyowa Hakko Europe1981Establishment of the Bio Business Headquarters2005Completion of the transition to an operating holding company(Phamaceuticals and Bio-chemicals are its main pillars)2007Announced a strategic alliance between Kyowa Hakko Group and Kirin Group.

[Kyowa Hakko Bio]

2008Establishment of Kyowa Hakko Bio
(succeed Bio-Chemical business from Kyowa Hakko Kogyo)

1956年首创用发酵方法生产L-谷氨酸 1988年成立北京事务所